NASDAQ:BBIO
BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc.'s revenue grew 126.3% in fiscal 2025 to $502.1M while operating margin rose to −104.2%, its highest in 7 years. Free cash flow was −$447.0M, −89.0% of revenue, and the diluted share count rose 2.9%.Summary generated from BridgeBio Pharma, Inc.'s SEC filings. Latest annual report filed Feb 24, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$502.1M
Revenue growth+126.3%
Revenue, 5-yr CAGR+127.4%
Gross margin95.8%
Operating margin−104.2%
Net margin−146.0%
ROICn/a
Return on equityn/a
Debt / equityn/a
Free cash flow−$447.0M
FCF margin−89.0%
Share count change+2.9%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 70 | 78 | 9 | 222 | 502 |
| Operating income | −577 | −512 | −607 | −593 | −523 |
| Net income | −586 | −485 | −653 | −543 | −733 |
| Free cash flow | −511 | −424 | −529 | −522 | −447 |
Recent filings
- 4Insider transaction report
Sep 21, 2026 - 8-KOther events
Aug 31, 2026 - 4Insider transaction report
Aug 20, 2026 - 8-KEntry into a material agreement
Aug 17, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 10, 2026 - 8-KResults of operations and financial condition
Aug 10, 2026 - 8-KOther events
Jul 22, 2026 - 8-KEntry into a material agreement
Jul 2, 2026